In the U.S., IGC develops phytocannabinoid-based treatments for epilepsy, seizures and cachexia. The goal in 2017, per CEO Ram Mukunda, is for the company to expand its cannabis-based portfolio, indicating that IGC will begin preclinical trials of IGC-501-Pain, IGC-502-Seizures and IGC-504-Cachexia (http://dtn.fm/bv91H). The company has formed a Phytocannabinoid Development Committee to review global medical facilities prior to beginning its preclinical trials. Toxicity evaluation and pharmacological assessments will be performed on each compound in preclinical trials.
Based in Bethesda, Maryland, IGC also manages real estate, leasing and development of properties. In India, it leases heavy equipment. In Malaysia, it manages commercial and residential real estate. In Hong Kong, the company previously operated a electronics business, but it has subsequently moved away from that activity. Long term, IGC aims to establish itself as a specialty pharmaceutical provider. It has already filed five provisional patents for its phytocannabinoid-based pharmaceutical and nutraceutical products in the U.S.
For more information, please refer to www.IGCInc.us
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
